NCT03723551 is a Phase 2 clinical trial of Afabicin in Bone or Joint Infection, sponsored by Debiopharm International SA.

Who is sponsoring NCT03723551?

NCT03723551 is sponsored by Debiopharm International SA.

What drugs are being tested in NCT03723551?

Interventions in NCT03723551: Afabicin, Standard of Care.

What condition does NCT03723551 study?

NCT03723551 studies Bone or Joint Infection.

Is NCT03723551 still recruiting?

NCT03723551 is currently terminated. Last updated 1 December 2025.

Last reviewed 2025-12-01 · How we verify

NCT03723551

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus

Terminated Phase 2 Last updated 1 December 2025

What this trial tests

Phase 2 trial testing Afabicin in Bone or Joint Infection in 67 participants. Terminated before completion.

Timeline

20 February 2019

Primary endpoint
23 April 2025

23 April 2025

Quick facts

Lead sponsor	Debiopharm International SA
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	67
Start date	20 February 2019
Primary completion	23 April 2025
Estimated completion	23 April 2025
Sites	19 locations across Georgia, South Africa, Ukraine

Drugs / interventions tested

Afabicin — full drug profile →
Standard of Care

Conditions studied

Bone or Joint Infection — all drugs for Bone or Joint Infection →

Sponsor

Debiopharm International SA — full company profile →

Who can join

18 and older, any sex, with Bone or Joint Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, active-controlled, open-label study to assess the safety, tolerability and efficacy of Afabicin in the treatment of participants with bone or joint infection due to Staphylococcus aureus \[both methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA)\] and/or coagulase-negative staphylococci (CoNS) and to compare it to standard of care (SOC).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics.
Miller WR, Arias CA. · · 2024 · cited 481× · PMID 38831030 · DOI 10.1038/s41579-024-01054-w
Antibiotics in the clinical pipeline in October 2019.
Butler MS, Paterson DL. · · 2020 · cited 174× · PMID 32152527 · DOI 10.1038/s41429-020-0291-8
Antibiotics in the clinical pipeline as of December 2022.
Butler MS, Henderson IR, Capon RJ, Blaskovich MAT. · · 2023 · cited 147× · PMID 37291465 · DOI 10.1038/s41429-023-00629-8
A Review of Antibacterial Candidates with New Modes of Action.
Butler MS, Vollmer W, Goodall ECA, Capon RJ, et al · · 2024 · cited 49× · PMID 39018341 · DOI 10.1021/acsinfecdis.4c00218
A Review of Fatty Acid Biosynthesis Enzyme Inhibitors as Promising Antimicrobial Drugs.
Bibens L, Becker JP, Dassonville-Klimpt A, Sonnet P. · · 2023 · cited 32× · PMID 36986522 · DOI 10.3390/ph16030425
Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms.
Koulenti D, Xu E, Song A, Sum Mok IY, et al · · 2020 · cited 27× · PMID 32019171 · DOI 10.3390/microorganisms8020191
Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses.
Melchiorri D, Rocke T, Alm RA, Cameron AM, et al · · 2025 · cited 18× · PMID 39454608 · DOI 10.1016/j.lanmic.2024.100992
Novel drug candidates against antibiotic-resistant microorganisms: A review.
Lim JS, Chai YY, Ser WX, Haeren AV, et al · · 2024 · cited 14× · PMID 38234674 · DOI 10.22038/ijbms.2023.71672.15593

Verify or expand the search:

Other Debiopharm International SA trials

Trials by the same sponsor.

NCT05147350 — Study of RP-6306 With FOLFIRI in Advanced Solid Tumors · Phase 1 · terminated
NCT05364944 — A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Ac · Phase 1 · terminated
NCT05147272 — Study of RP-6306 With Gemcitabine in Advanced Solid Tumors · Phase 1 · terminated
NCT04962724 — A Study to Evaluate the Absorption, Metabolism, and Excretion and Absolute Bioavailability of Xevinapant in Healthy Male · Phase 1 · completed
NCT03968653 — Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03723551 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Debiopharm International SA
Last refreshed: 1 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03723551.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing